Breaks Categories: News

WednesdayDec 15, 2021 12:14 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Notice of Allowance from U.S. Patent Office for Exclusive Anxiety Disorder Treatment

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has been awarded a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”). The award is for CYBN’s patent application related to CYB004, an investigational deuterated psychedelic tryptamine compound developed for the potential treatment of anxiety disorders. According to the announcement, allowed claims under the award also include other forms of deuterated psychedelic tryptamine. This award expands Cybin’s intellectual property portfolio and strengthens the company’s position as leading innovator in developing putative psychedelic compounds. According to the company, CYB004 has the potential to effectively treat…

Continue Reading

FridayDec 10, 2021 12:24 pm

PsychedelicNewsBreaks – Mind Medicine (‘MindMed’) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) Engages with FDA for Development of the ‘MSMS’

Mind Medicine (“MindMed”) (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, recently met with the United States Food and Drug Administration (“FDA”) Center for Devices and Radiological Health (“CDRH”) with consultation from the Center for Drug Evaluation and Research (“CDER”). The device pre-submission meeting that took place on Oct. 25, 2021, was concerning several key points for ongoing development of the MindMed Session Monitoring System (“MSMS”). MindMed presented the FDA with a working Indications for Use (“IFU”) statement and a development roadmap, which describe technology and infrastructure for the collection of precise, multimodal, multivalent data…

Continue Reading

ThursdayDec 09, 2021 2:43 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Financing to Provide Runway for Key Milestones

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced its entry into an agreement with an investor to complete a non-brokered private placement (the “financing”) of a convertible secured subordinated debenture in the principal amount of C$5.5 million. According to the update, the financing is expected to close on Dec. 10, 2021. “I would like to thank our incredible strategic shareholder for stepping up in a tough, volatile market and continuing to support and expand upon your large stake in Mydecine,” said the…

Continue Reading

ThursdayDec 09, 2021 8:30 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Announces Establishment of Regulatory Advisory Board, Strategic Appointments

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced that it has formed a regulatory advisory board (“RAB”) and has appointed Joga Gobburu, B.Pharm (Hons), M.Sc. (Hons), Ph.D., M.B.A., and Mary Melnyk, M.Sc., Ph.D., as members. Dr. Gobburu is a world-recognized scientific leader in pharmacometrics and a professor at the School of Pharmacy and the School of Medicine at the University of Maryland. Dr. Melnyk is an expert in manufacturing and regulatory requirements for pharmaceutical and medical device development. She is the senior regulatory…

Continue Reading

WednesdayDec 08, 2021 11:38 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Moving Rapidly to Progress CYB003 Toward Clinical Development

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced a confirmed scientific advice meeting with the UK Medical and Healthcare Products Regulatory Agency (“MHRA”) for the first quarter of calendar year 2022. According to the update, this program milestone brings Cybin closer to advancing its lead investigational candidate CYB003 into clinical development for the treatment of major depressive disorder (“MDD”) and alcohol use disorder (“AUD”). “Encouraged by positive preclinical findings that demonstrated the advantages of our novel deuterated psilocybin analog over oral psilocybin for the treatment of mental health, we are moving…

Continue Reading

MondayDec 06, 2021 12:24 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Patent Application Covering Multiple Families of Psilocin Analogs

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has filed a full patent application covering multiple families of psilocin analogs. According to the update, the application includes solutions to directly address further precision in delivery control and shelf stabilization of psilocin, psilocybin’s active metabolite, both of which are critical for use in the medical setting. “The goal of creating these improved second-generation compounds is to enable safer, more effective treatments for patients along with improved management of dosage and drug behavior…

Continue Reading

FridayDec 03, 2021 11:29 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at 2nd Annual H.C. Wainwright Psychedelics Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present at the Second Annual H.C. Wainwright Psychedelics Conference. The event is slated to be held virtually on Dec. 6, 2021. Tryp’s chairman and CEO Greg McKee will provide an overview of the business and its pipeline, including the upcoming phase 2a clinical trials in fibromyalgia, phantom limb pain, binge eating disorder and other indications. McKee's presentation will be available on-demand through the H.C. Wainwright conference portal beginning at 7:00 a.m. ET. on Monday, Dec.…

Continue Reading

FridayDec 03, 2021 9:30 am

PsychedelicNewsBreaks – FSD Pharma Inc.’s (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Lucid-MS Featured in InvestmentPitch Video, CEO to Present at H.C. Wainwright Psychedelics Virtual Conference

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today shared preclinical data demonstrating the potentially disease-modifying effects of Lucid-MS, its lead drug candidate for the potential treatment of multiple sclerosis in the animal models of MS. According to the update, InvestmentPitch.com has produced a video discussing the news. Based on over a decade of research, Lucid-MS is a patented neuroprotective new chemical entity that affects protein citrullination and myelin structure, which are associated with the severity of MS lesions. FSD Pharma has released a video…

Continue Reading

ThursdayDec 02, 2021 11:31 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Plans Opening of Two Additional Ketamine Wellness Centers

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, announced that subsidiary Ketamine Wellness Centers (“KWC”) is planning to open new clinics in Salt Lake City, Utah, and Reno, Nevada; the clinics are slated to open by February 2022. The new clinics will bring the total of KWC locations to 12; the company currently has 10 ketamine infusion treatment clinics in eight different states and is positioned as the largest chain of wellness centers in the country. The Utah location will be one of KWC’s largest clinics, and the Reno clinic is strategically…

Continue Reading

ThursdayDec 02, 2021 10:00 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Green Light from FDA for Clinical Study in Fibromyalgia

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced its receipt of confirmation from the U.S. Food and Drug Administration (“FDA”) that its review of Tryp’s Investigational New Drug (“IND”) application is complete and that the company may proceed with its clinical study in fibromyalgia. The trial, which the company expects to initiate in 2022, is being conducted with Kevin Boehnke, Ph.D. from the University of Michigan and will evaluate Tryp’s oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy. “The upcoming phase 2a study with…

Continue Reading